Welcome to our dedicated page for IRONWOOD PHARMACEUTICALS SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRONWOOD PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRONWOOD PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ironwood Pharmaceuticals filed a Form 144 reporting a proposed sale of 1,351 shares of Class A common stock on Nasdaq, with an aggregate market value of $1,188.88. The sale is listed with an approximate sale date of 08/11/2025. The filer acquired 4,000 shares as a Restricted Stock Unit award on 08/16/2023, and no securities of the issuer were reported sold by the filer in the past three months.
The filing includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer. The shares to be sold amount to approximately 0.000835% of the 161,819,848 shares outstanding, indicating a very small proposed disposition relative to the company’s market capitalization.
Ironwood Pharmaceuticals Form 144 reports that Tammi Gaskins proposes to sell 1,406 shares of Class A common stock on 08/11/2025 through E Trade (Nasdaq), with an aggregate market value of $1,237.28. The filing states these shares were acquired as 4,000 restricted stock units granted on 08/16/2023.
The notice also discloses a prior sale of 2,563 shares on 05/16/2025 for gross proceeds of $1,486.54. The filer affirms they do not possess undisclosed material adverse information.